Immunotherapies have emerged as effective treatments for immune system-related diseases, such as cancer and inflammatory diseases. Although immunotherapeutics are effective not all patients benefit and side effects vary greatly. Thus, there is an unm...
Task 3.6
Nanobody labelling optimisation for PET and OI...
Description
General Design
- Type
- Cohort study
- Start/End data collection
- not available
Organisations
Lead organisations
- University of TübingenGermanyhttps://www.uni-tuebingen.de/en/university.html
- Pfizer (United Kingdom)United Kingdom of Great Britain and Northern Ireland (the)http://www.pfizer.co.uk/
- Amsterdam UMC Location Vrije Universiteit Amsterdam (VUMC)Netherlands (the)https://vumc.nl
- Takeda (United Kingdom)United Kingdom of Great Britain and Northern Ireland (the)http://www.takedacam.com/
- University Medical Center Groningen (UMCG)Netherlands (the)https://www.umcg.nl
- Vrije Universiteit Brussel (VUB)Belgiumhttp://www.vub.ac.be/en/
- University of Münster (UM)Germanyhttps://www.uni-muenster.de
Additional organisations
- Antaros Medical (Sweden)Swedenhttps://antarosmedical.com/
- Bayer (Germany)Germanyhttp://www.gesundheit.bayer.de/de/index.php
- Roche (Switzerland)Switzerlandhttp://www.roche.ch/en/index.htm
- Vall d'Hebron Institut de Recerca (VHIR; VHIR-CERCA)Spainhttps://vhir.vallhebron.com
- Vall d'Hebron Institute of Oncology (VHIO; VHIO-CERCA)Spainhttps://www.vhio.net
Data originator, Data holder, Data provider
- ImaginAb (United States)United States of America (the)https://www.imaginab.com/
- Janssen (Belgium)Belgiumhttps://www.janssen.com/belgium/
- LygatureNetherlands (the)https://www.lygature.org/
- University of CambridgeUnited Kingdom of Great Britain and Northern Ireland (the)https://www.cam.ac.uk
Networks
Part of networks...